BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 19487913)

  • 1. Severe radiation dermatitis in patients with locally advanced head and neck cancer treated with concurrent radiation and cetuximab.
    Koutcher LD; Wolden S; Lee N
    Am J Clin Oncol; 2009 Oct; 32(5):472-6. PubMed ID: 19487913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Grade 3/4 dermatitis in head and neck cancer patients treated with concurrent cetuximab and IMRT.
    Studer G; Brown M; Salgueiro EB; Schmückle H; Romancuk N; Winkler G; Lee SJ; Sträuli A; Kissling B; Dummer R; Glanzmann C
    Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):110-7. PubMed ID: 20732757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes.
    Giro C; Berger B; Bölke E; Ciernik IF; Duprez F; Locati L; Maillard S; Ozsahin M; Pfeffer R; Robertson AG; Langendijk JA; Budach W
    Radiother Oncol; 2009 Feb; 90(2):166-71. PubMed ID: 18977050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and management of severe cutaneous side effects in head-and-neck cancer patients during concurrent radiotherapy and cetuximab.
    Bölke E; Gerber PA; Lammering G; Peiper M; Müller-Homey A; Pape H; Giro C; Matuschek C; Bruch-Gerharz D; Hoffmann TK; Gripp S; Homey B; Budach W
    Strahlenther Onkol; 2008 Feb; 184(2):105-10. PubMed ID: 18259703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiotherapy combined with cetuximab for locally advanced head and neck cancer: results and toxicity.
    Acevedo-Henao CM; Valette G; Miglierini P; Lefur E; Pradier O
    Cancer Radiother; 2012 Oct; 16(7):601-3. PubMed ID: 23089070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis.
    Birnbaum A; Dipetrillo T; Rathore R; Anderson E; Wanebo H; Puthwala Y; Joyce D; Safran H; Henderson D; Kennedy T; Ready N; Sio TT
    Am J Clin Oncol; 2010 Apr; 33(2):144-7. PubMed ID: 19786848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cetuximab with radiotherapy in patients with loco-regionally advanced squamous cell carcinoma of head and neck unsuitable or ineligible for concurrent platinum-based chemo-radiotherapy: Ready for routine clinical practice?
    Agarwal JP; Gupta T; Kalyani N; Budrukkar A; Laskar SG; Murthy V; Kumar P; Narohna V; Pai P; Chaturvedi P; D'cruz AK
    Indian J Cancer; 2011; 48(2):148-53. PubMed ID: 21768657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial using the proteasome inhibitor bortezomib and concurrent chemoradiotherapy for head-and-neck malignancies.
    Kubicek GJ; Axelrod RS; Machtay M; Ahn PH; Anne PR; Fogh S; Cognetti D; Myers TJ; Curran WJ; Dicker AP
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1192-7. PubMed ID: 22245208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer.
    Koutcher L; Sherman E; Fury M; Wolden S; Zhang Z; Mo Q; Stewart L; Schupak K; Gelblum D; Wong R; Kraus D; Shah J; Zelefsky M; Pfister D; Lee N
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):915-22. PubMed ID: 20947269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of severe bio-radiation dermatitis induced by radiotherapy and cetuximab in patients with head and neck cancer: emphasizing the role of calcium alginate dressings.
    Bonomo P; Desideri I; Loi M; Ciccone LP; Lo Russo M; Becherini C; Greto D; Simontacchi G; Pimpinelli N; Livi L
    Support Care Cancer; 2019 Aug; 27(8):2957-2967. PubMed ID: 30569265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Concurrent chemoradiotherapy (CRT) with S-1 and cisplatin (CDDP) in patients (pts) with locally advanced head and neck cancer (HNC)].
    Tahara M
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():167-71. PubMed ID: 16897996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm.
    Pfister DG; Su YB; Kraus DH; Wolden SL; Lis E; Aliff TB; Zahalsky AJ; Lake S; Needle MN; Shaha AR; Shah JP; Zelefsky MJ
    J Clin Oncol; 2006 Mar; 24(7):1072-8. PubMed ID: 16505426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiochemotherapy with cetuximab, cisplatin, and amifostine for locally advanced head and neck cancer: a feasibility study.
    Koukourakis MI; Tsoutsou PG; Karpouzis A; Tsiarkatsi M; Karapantzos I; Daniilidis V; Kouskoukis C
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):9-15. PubMed ID: 19744802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cetuximab plus radiotherapy in patients with unresectable locally advanced squamous cell carcinoma of head and neck region--a open labelled single arm phase II study.
    Dattatreya S; Goswami C
    Indian J Cancer; 2011; 48(2):154-7. PubMed ID: 21768658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines.
    Bernier J; Russi EG; Homey B; Merlano MC; Mesía R; Peyrade F; Budach W
    Ann Oncol; 2011 Oct; 22(10):2191-200. PubMed ID: 21606209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective, multicenter study of the tolerance of induction chemotherapy with docetaxel, Cisplatin, and 5-Fluorouracil followed by radiotherapy with concomitant cetuximab in 46 cases of squamous cell carcinoma of the head and neck.
    Buiret G; Combe C; Favrel V; Pommier P; Martin L; Ecochard R; Fayette J; Tartas S; Ramade A; Céruse P
    Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):430-7. PubMed ID: 19775831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of dermatitis in patients with locally advanced squamous cell carcinoma of the head and neck receiving cetuximab and radiotherapy.
    Cabezón-Gutiérrez L; Khosravi-Shahi P; Escobar-Álvarez Y
    Oral Oncol; 2012 Apr; 48(4):293-7. PubMed ID: 22137799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Phase 1/2 ACCEPT Trial: Concurrent Cetuximab and Intensity Modulated Radiation Therapy with Carbon Ion Boost for Adenoid Cystic Carcinoma of the Head and Neck.
    Adeberg S; Akbaba S; Lang K; Held T; Verma V; Nikoghosyan A; Bernhardt D; Münter M; Freier K; Plinkert P; Hauswald H; Herfarth K; Rieken S; Debus J; Jensen AD
    Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):167-173. PubMed ID: 31586664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer.
    Kao J; Genden EM; Gupta V; Policarpio EL; Burri RJ; Rivera M; Gurudutt V; Som PM; Teng M; Packer SH
    Cancer; 2011 Jan; 117(2):318-26. PubMed ID: 20830768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe gastrointestinal bleeding in patients with locally advanced head and neck squamous cell carcinoma treated by concurrent radiotherapy and Cetuximab.
    Murakami N; Yoshimoto S; Matsumoto F; Ueno T; Ito Y; Watanabe S; Kobayashi K; Harada K; Kitaguchi M; Sekii S; Takahashi K; Yoshio K; Inaba K; Morota M; Sumi M; Saito Y; Itami J
    J Cancer Res Clin Oncol; 2015 Jan; 141(1):177-84. PubMed ID: 25119987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.